Effects of Alpha-GPC on Muscle Power, GH Levels, and Cognitive Function
Palo Alto (17 mi)Overseen byTim Ziegenfuss, PhD
Age: 18 - 65
Sex: Male
Travel: May be covered
Time Reimbursement: Varies
Trial Phase: N/A
Waitlist Available
Sponsor: Lindenwood University
Trial Summary
What is the purpose of this trial?Purpose: To determine the effects of low dose and high dose Alpha-GPC on cognitive performance, muscle performance, and serum growth hormone levels.
Design: Randomized, three-arm, within-subject crossover
Study Participants: 21 apparently healthy men to be recruited at a single investigational center in Northeast Ohio
4 Study Visits
Study Visit 1: Participants will be screened for participation (i.e., medical history, routine blood work, background baseline diet)
Study Visit 2: Participants will ingest one of three supplements (a low dose α-GPC, a high dose α-GPC, or a placebo). Subjects will complete visual analog scale (VAS) questionnaires (assessing mood, motivation, alertness, and concentration) and a cognitive battery (Stroop, Flanker, and N-Back tests) 60 min post ingestion and approximately 3 hours post-ingestion, undergo upper body and lower body power testing and a lower body bout of moderate-intensity exercise 90 min post-ingestion. Also, subjects will undergo blood draws for levels of growth hormone at baseline (prior to supplementation) and 5, 15, 30, and 60 min post lower body bout of exercise. Vital signs and comprehensive side effect profile/ adverse event monitoring will take place throughout the duration of the study. The study will be conducted following ICH-GCP guidelines to ensure subject safety and scientific integrity of the data.
Study Visit 3 and 4 Identical to visit 2 with exception of different supplementation being provided. Supplement administration was randomized using a Latin square approach to reduce variability and enhance statistical power
Primary Outcomes: Upper and lower body peak force production, peak power production, and peak velocity
Secondary Outcomes: Cognitive performance on the Stroop test, Flanker, and N-Back test, serum growth hormone levels, mood, motivation, alertness, and concentration (as assessed by visual analog scales).
Tertiary/Safety Outcomes: Vital signs, side effect profile/AE monitoring
Eligibility Criteria
Treatment Details
3Treatment groups
Active Control
Placebo Group
Group I: Low Dose Alpha-GPCActive Control1 Intervention
315 mg dose of alpha-glycerylphosphorycholine (alpha-GPC)
Group II: High Dose Alpha-GPCActive Control1 Intervention
630 mg dose of alpha-glycerylphosphorycholine (alpha-GPC)
Group III: PlaceboPlacebo Group1 Intervention
Placebo
Find a clinic near you
Research locations nearbySelect from list below to view details:
Center for Applied Health SciencesCanfield, OH
Loading ...
Who is running the clinical trial?
Lindenwood UniversityLead Sponsor
NNB NutritionCollaborator